- Date 7 Dec 2020
Biofidelity Ltd, the cancer diagnostics company, have announced the opening of its new headquarters as it continues its significant recruitment ahead of commercialization of its first products. The Company has expanded into more than 500 square meters of office and laboratory space on Cambridge Science Park, one of Europe’s leading technology hubs and home to more than 130 businesses.
The laboratories will support Biofidelity’s development of diagnostic assays designed to revolutionize access to best-in-class cancer diagnosis.
The move to Cambridge Science Park follows a number of important developments during 2020, including:
- Completion of a Series A financing raising $12 million, enabling acceleration of plans to launch Biofidelity’s unique platform, which has the potential to change the dynamics of cancer diagnosis and treatment
- Sustained progress towards launch of the first genetic panels targeting guideline-recommended markers in non-small cell lung cancer in the US
- Collaboration with Agilent Technologies, a global leader in life sciences and diagnostics, confirming Biofidelity molecular assays’ ability to detect key lung cancer mutations, dramatically increasing effectiveness and speed of diagnosis
- Substantial strengthening of the senior management team, including the appointment of Dr Heiner Dreismann as Chairman and Stephen Miller as Chief Commercial Officer, based in the US